The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
By interfering with RNA, drug company Santaris may have launched a new generation of drugs. Following a successful animal trial, an unusual new drug has sparked interest due to its ability to lower cholesterol and block the Hepatitis C virus.
Continue reading »Currently in clinical trials for safety, the first human has completed treatment on the therapeutic DNA vaccine known as ChronVac-C®. By utilizing an innovative electroporation-based DNA delivery system, ChronVac-C® now has concrete evidence of its safety and ability to invoke the desired immune response against Hepatitis C.
Continue reading »Experts in the field agree that STAT-C drugs combined with pegylated interferon and possibly ribavirin are the future for treating Hepatitis C. Learn more about STAT-C, as well as the three factors limiting interferon treatment.
Continue reading »Animal studies of Anadys Pharmaceutical's new non-nucleoside Hepatitis C inhibitor have delivered some hopeful results. Although the subjects were primates, ANA598's demonstration of rapid viral load decline, favorable pharmacokinetics, safety, and tolerability profiles support its continued development.
Continue reading »A substantial, five-year study confirms that when it comes to treating Hepatitis C, one size does not fit all. When combined with pegylated interferon, researchers discovered basing the dosage of ribavirin on a patient's weight could yield better results than giving all participants a flat dosage of ribavirin. In addition, the weight-based ribavirin dosage demonstrated a clear advantage to African Americans with Hepatitis C, whose outcomes has previously lagged behind those of Caucasian patients.
Continue reading »In collaboration with health centers across the globe, researchers at Duke University Medical Center are excited about a once daily pill for increasing blood platelet counts. To help patients complete antiviral therapy, the researchers found that eltrombopag effectively raises blood platelets in those with low platelet counts and cirrhosis of the liver due to Hepatitis C.
Continue reading »Molecularly different than pegylated interferon, consensus interferon offers hope to non-responders. This retrospective study on U.S. veterans with Hepatitis C demonstrates that those with Hepatitis C RNA remaining after interferon-ribavirin therapy may have another option for future treatment.
Continue reading »OctoPlus has reported positive results from a Phase IIa trial for the Hepatitis C drug Locteron. Thus far, Locteron is encouraging due to its convenient dosing schedule, tolerability and Hepatitis C anti-viral activity.
Continue reading »Delivering encouraging news, pharmaceutical giant Roche shares results of two of its leading HCV drugs. As the result of a Phase IIa trial that combined Pegasys and Copegus with R1626, the Hepatitis C virus was undetectable in 81 percent of the study's participants. In collaboration with Pharmasset, a Phase I study of R7128 also demonstrated great promise against the virus.
Continue reading »Preliminary results from a Phase II trial on Schering-Plough's experimental Hepatitis C drug Boceprevir are promising. If the results of this study prove to be reproducible and the drug is safe, Boceprevir may help many more people defeat the Hepatitis C virus.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
